Epstein-Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor

Transplantation

Volumn 67, Issue 10, 1999, Pages 1373-1375

  Parry Jones, Nilima ^b   Haque, Tanzina ^b   Ismail, Medmat ^b   Jones, Lydia ^b   Hale, Geoff ^b   Waldmann, Herman ^b   Gordon Smith, Edward C ^b   Crawford, Dorothy H ^b   Marsh, Judith C W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; THYMOCYTE ANTIBODY; VIRUS ANTIBODY;

ADULT; ANEMIA; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS DETECTION;

ADULT; ANEMIA, APLASTIC; B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; TISSUE DONORS;

EID: 0033609321     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199905270-00015     Document Type: Article

References (10)

1. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders BLPD after non-HLA identical BMT in children. Bone Marrow Transplant 1996; 18: 377.
2. Zutter M, Martin P, Sale G ,et al. Epstein-Barr lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520.
3. Papadopoulos E, Ladyani M, Emmanual D, et al. Infusions of donor leucocytes to treat Epstein-Barr virus associated lyphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185.
4. Hale G, Waldmann H. For CAMPATH Users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell depleted marrow transplants. Blood 1998; 91: 3079.
5. Smith CA, Ng CYC, Heslop HE, et al. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Haematol 1995; 4: 73.
6. Carmichael A, Jin X, Sissons P, Borysiewicz LJ. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: Differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993; 177: 249.
7. Hale G, Waldmann H. For Campath users. Recent results using Campath-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996; 17: 305.
8. Gratama JW, Oosterveer MAP, Zwaan FE, Lepoutre J, Klein G, Ernberg I. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency. Proc Natl Acad Sci USA 1988; 85: 8693.
9. Rooney CM, Smith CA, Ng CYC, et al. Use of gene modified virus specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
10. Bader P, Klingebiel T, Klingel K, et al. Remission of a lymphoproliferative disorder occurring after second BMT from and unrelated donor in a 5 year old boy with severe aplastic anaemia. Bone Marrow Transplant 1995; 16: 479.